ADPS™ KRAS Mutation Test Kit
- Detection target: 19 mutations in KRAS exon 2 and 3 (codon 12, 13 and 61)
- Sample type: DNA extracted from FFPE, frozen, and fresh cancer tissue or liquid biopsy
- Detection Sensitivity:0.1%
- Detection Specificity: ≥ 99.0%
- Precision (% CV): ≤ 5% (CV, coefficient of variation)
INTENDED USE
In colorectal cancer, Erbitux (cetuximab) and Vectibix (panitumumab) are approved drugs that target EGFR. The presence of KRAS mutations affects the response to treatment with cetuximab and panitumumab, often leading to a negative response in CRC patients. Therefore, detecting KRAS mutations may help guide the treatment of CRC patients.
The ADPS™ KRAS Mutation Test Kit detects 19 mutations in exons 2 and 3 of the KRAS gene with a sensitivity of 0.1%. It is designed for testing both tissue and plasma samples with a single kit.
- Fast
- Sensitive
- Qualitative
- CE-IVD
Validated Instruments
